Alector, Inc. ALEC
We are a clinical-stage biotechnology company developing therapies for neurodegenerative diseases, with a focus on areas of high unmet medical need. Our work is informed by advances in disease biology, including the roles of misfolded or deficient proteins, lysosomal dysfunction, and immune and neuronal pathway disruption.
Our objective is to develop product candidates that address disease through targeted mechanisms, such as removing pathogenic proteins, replacing deficient proteins, and restoring normal cellular function. We are advancing a portfolio of programs focused on genetically validated targets, supported by our expertise in drug development, protein engineering, and antibody discovery.
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $21.0M | $100.6M | $97.1M | $133.6M | $207.1M | $21.1M | $21.2M | $27.5M | $2.9M | — |
| R&D | $123.1M | $185.9M | $192.1M | $210.4M | $189.4M | $156.9M | $100.5M | $73.0M | $29.9M | — |
| SG&A | $54.0M | $59.6M | $56.7M | $61.0M | $55.0M | $59.4M | $35.1M | $11.9M | $6.5M | — |
| Total operating expenses | $177.1M | $245.6M | $248.8M | $271.5M | $244.4M | $216.3M | $135.6M | $85.0M | $36.4M | — |
| Operating income | -$156.0M | -$145.0M | -$151.7M | -$137.8M | -$37.4M | -$195.2M | -$114.4M | -$57.3M | -$32.7M | — |
| Pre-tax income | -$142.8M | -$118.9M | -$125.1M | -$130.1M | -$36.3M | -$190.2M | -$105.4M | — | — | — |
| Income tax | $168.0K | $128.0K | $5.2M | $3.3M | $0 | $0 | $0 | — | — | — |
| Net income | -$143.0M | -$119.0M | -$130.0M | -$133.3M | -$36.3M | -$190.2M | -$105.4M | -$52.2M | -$32.5M | — |
| EPS, basic | -1.39 | -1.23 | -1.56 | -1.62 | -0.45 | -2.45 | — | — | — | — |
| EPS, diluted | -1.39 | -1.23 | -1.56 | -1.62 | -0.45 | -2.45 | -1.71 | -4.62 | -3.55 | — |
| Shares, diluted (wtd. avg.) | $103.0M | $96.6M | $83.7M | $82.5M | $80.4M | $77.8M | — | — | — | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $65.8M | $33.0M | $76.1M | $155.8M | $330.6M | $51.4M | $91.1M | $66.9M | $32.5M | $51.0M |
| Short-term investments | $190.2M | $380.4M | $474.3M | $558.5M | $406.1M | $363.3M | $263.4M | $224.9M | — | — |
| Total current assets | $266.5M | $424.8M | $565.8M | $726.4M | $749.7M | $421.5M | $357.4M | $293.2M | — | — |
| Property, plant and equipment | $10.8M | $17.1M | $21.9M | $25.5M | $27.3M | $30.2M | $33.9M | $10.9M | — | — |
| Total assets | $293.2M | $468.3M | $621.8M | $787.6M | $814.7M | $488.3M | $421.9M | $308.4M | — | — |
| Accounts payable | $1.7M | $2.2M | $3.8M | $4.2M | $4.7M | $3.0M | $278.0K | $126.0K | — | — |
| Short-term debt | $366.0K | $0 | — | — | — | — | — | — | — | — |
| Total current liabilities | $69.5M | $125.1M | $177.9M | $93.8M | $139.6M | $68.1M | $62.0M | $47.9M | — | — |
| Long-term debt | $9.3M | $9.4M | $0 | — | — | — | — | — | — | — |
| Total liabilities | $262.6M | $341.5M | $487.7M | $573.2M | $513.9M | $220.7M | $227.2M | $195.2M | — | — |
| Retained earnings | -$972.1M | -$829.1M | -$710.1M | -$579.7M | -$446.4M | -$410.0M | -$219.8M | -$114.4M | — | — |
| Total equity | $30.6M | $126.8M | $134.2M | $214.4M | $300.7M | $267.5M | $194.7M | -$97.4M | -$52.0M | -$24.9M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$184.0M | -$229.9M | -$184.2M | -$20.3M | $298.6M | -$166.7M | -$99.3M | $127.5M | -$17.8M | — |
| Stock-based compensation | $26.7M | $39.5M | $42.8M | $46.1M | $40.8M | $30.5M | $16.3M | $6.9M | $5.4M | — |
| Capital expenditure | $41.0K | $1.3M | $2.4M | $4.1M | $3.2M | $5.0M | $15.3M | $1.9M | $801.0K | — |
| Investing cash flow | $196.6M | $107.1M | $101.9M | -$159.0M | -$49.7M | -$105.1M | -$48.9M | -$224.1M | -$801.0K | — |
| Financing cash flow | $20.2M | $81.5M | $2.5M | $4.5M | $30.3M | $232.1M | $172.4M | $131.1M | -$15.0K | — |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001193125-26-186928.
Others in SIC 2836
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| AMGN | AMGEN INC | $236.38B | 30.7x | 10.0% |
| GILD | GILEAD SCIENCES, INC. | $187.23B | 22.3x | 2.4% |
| MRNA | Moderna, Inc. | $58.11B | — | -39.9% |
| RVMD | Revolution Medicines, Inc. | $45.01B | — | — |
| BIIB | BIOGEN INC. | $32.60B | 25.1x | 2.2% |
| SCNI | Scinai Immunotherapeutics Ltd. | $25.80B | — | 99.2% |
| NBIX | NEUROCRINE BIOSCIENCES INC | $15.82B | 33.3x | 21.4% |
| EXEL | EXELIXIS, INC. | $14.62B | 21.2x | 7.0% |